ArticleBiomarker research2013
Metabolomic analyses for atherosclerosis, diabetes, and obesity.
Article in Biomarker research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies.Metabolomics : Official journal of the Metabolomic Society · 2019Pooled it
- Electroacupuncture Reduces Waistline in Patients with Abdominal Obesity: A Randomized Controlled Trial with Mechanistic Analysis of Lipidomic and Intestinal Microbiota.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Trial
- Trial
- Untargeted Metabolomics Identifies N-Lactoyl-Amino Acids as Dose-Responsive Plasma Biomarkers of Metformin Adherence in Type 2 Diabetes.Clinical pharmacology and therapeutics · 2026Article
- Lifestyles, metabolome and diabetic kidney disease: a cohort study.QJM : monthly journal of the Association of Physicians · 2026Article
- Circulating amino acids and Type 2 diabetes in a Latin American population-based cohort.Cardiovascular diabetology · 2026Article
- Urinary biomarkers of diabetic kidney disease.World journal of diabetes · 2026Review
- Acupuncture-assisted lifestyle intervention improve the metabolic status and spontaneous brain activity of type 2 diabetes Mellitus patients: a randomized, clinical trial.Diabetology & metabolic syndrome · 2024Article
- Metabolomic Effects of Liraglutide Therapy on the Plasma Metabolomic Profile of Patients with Obesity.Metabolites · 2024Article
- Metabolomics in diabetic nephropathy: Unveiling novel biomarkers for diagnosis (Review).Molecular medicine reports · 2024Review
- Lipid metabolism disorder in diabetic kidney disease.Frontiers in endocrinology · 2024Review
- Lipidomics Profiling Reveals Serum Phospholipids Associated with Albuminuria in Early Type 2 Diabetic Kidney Disease.ACS omega · 2023Article
- Editorial: Debates in cardiovascular pharmacology and drug discovery: 2022.Frontiers in cardiovascular medicine · 2023Article
- Metabolomics in asthma: A platform for discovery.Molecular aspects of medicine · 2022Review
- Effect of Acupoint Catgut Embedding for Middle-Aged Obesity: A Multicentre, Randomised, Sham-Controlled Trial.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Mechanism of Action of Acupuncture in Obesity: A Perspective From the Hypothalamus.Frontiers in endocrinology · 2021Review
- Old and New Biomarkers Associated with Endothelial Dysfunction in Chronic Hyperglycemia.Oxidative medicine and cellular longevity · 2021Review
- Biomarker Discovery in Atherosclerotic Diseases Using Quantitative Nuclear Magnetic Resonance Metabolomics.Frontiers in cardiovascular medicine · 2021Review
- Research progress and perspective in metabolism and metabolomics of psoriasis.Chinese medical journal · 2020Article
- Plasma Metabolic Signature of Atherosclerosis Progression and Colchicine Treatment in Rabbits.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Insulin resistance associated with type 2 diabetes mellitus (T2DM), obesity, and atherosclerosis is a global health problem. A portfolio of abnormalities of metabolic and vascular homeostasis accompanies T2DM and obesity, which are believed to conspire to lead to accelerated atherosclerosis and premature death. The complexity of metabolic changes in the diseases presents challenges for a full understanding of the molecular pathways contributing to the development of these diseases. The recent advent of new technologies in this area termed "Metabolomics" may aid in comprehensive metabolic analysis of these diseases. Therefore, metabolomics has been extensively applied to the metabolites of T2DM, obesity, and atherosclerosis not only for the assessment of disease development and prognosis, but also for the biomarker discovery of disease diagnosis. Herein, we summarize the recent applications of metabolomics technology and the generated datasets in the metabolic profiling of these diseases, in particular, the applications of these technologies to these diseases at the cellular, animal models, and human disease levels. In addition, we also extensively discuss the mechanisms linking the metabolic profiling in insulin resistance, T2DM, obesity, and atherosclerosis, with a particular emphasis on potential roles of increased production of reactive oxygen species (ROS) and mitochondria dysfunctions.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.